Pfizer said on May 10 it had agreed to pay $11.6 billion for the remaining part of Biohaven Pharmaceutical it does not own. Pfizer will pay $148.50 per share, a 79% premium to where the shares closed on May 9.
Biohaven’s lead drug, Nurtec ODT, is approved for the prevention and treatment of migraine. It was approved in the United States in 2020 and had revenue of $463 million in 2021. Pfizer has a 2.6% stake in Biohaven it acquired as part of a collaboration agreement signed in November. As part of that deal, Pfizer bought $350 million of shares in Biohaven at $173 a share and received the rights to sell Nurtec ODT outside the United States.
As part of the May 10 deal, Biohaven shareholders, including Pfizer, will also receive shares in a new public company that will retain rights to some Biohaven drugs that are in development. The new company will operate under the Biohaven name and will be capitalized with $275 million of cash. It may also receive royalties from Pfizer if annual net sales of Nurtec ODT and a potential migraine drug Pfizer is buying as part of the deal exceed certain thresholds.The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer to Buy Rest of Biohaven for $11.6 BillionPfizer said it agreed to buy the rest of Biohaven Pharmaceutical for about $11.6 billion, giving drugmaker full ownership of the Nurtec ODT migraine franchise It's better to fail in originality than to succeed in imitation that was the word you have to me, and behold I'm doing great today and that's because I help to your advices Geoffrey100k it's been cool ever since I started investing with you
Source: WSJ - 🏆 98. / 63 Read more »
Rare cases of COVID returning pose questions for Pfizer pillA small number of COVID-19 patients are relapsing after taking Pfizer's antiviral pill, raising questions about the drug at the center of the U.S. response effort. Screw big Pharma. Take hydroxychloroquine. It works & its cheap in most countries. Let’s see you are triple jabbed and now taking paxlovid. You can’t make this up. It’s all about lining the pockets of BigPharma wake up people! Of course they do DISCUSS THE PFIZER DATA RELEASE ON THE JAB.
Source: wjxt4 - 🏆 246. / 63 Read more »
Rare cases of COVID-19 returning pose questions for Pfizer pillPaxlovid has become the go-to option against COVID-19 because of its at-home convenience and impressive results in heading off severe disease.
Source: PennLive - 🏆 463. / 53 Read more »
Rare cases of COVID returning pose questions for Pfizer pillA small number of COVID-19 patients are relapsing after taking Pfizer's antiviral pill, raising questions about the drug at the center of the U.S. response effort.
Source: KPRC2 - 🏆 80. / 68 Read more »
Rare Cases Of COVID Returning Pose Questions For Pfizer PillA small number of COVID-19 patients are relapsing after taking Pfizer's antiviral pill, raising questions about the drug at the center of the U.S. response effort.
Source: HuffPostWomen - 🏆 27. / 68 Read more »
Pfizer to Buy Rest of Biohaven for $11.6 BillionPfizer said it agreed to buy the rest of Biohaven Pharmaceutical for about $11.6 billion, giving drugmaker full ownership of the Nurtec ODT migraine franchise It's better to fail in originality than to succeed in imitation that was the word you have to me, and behold I'm doing great today and that's because I help to your advices Geoffrey100k it's been cool ever since I started investing with you
Source: WSJ - 🏆 98. / 63 Read more »